Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies

Trial Profile

Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Teprotumumab (Primary) ; Bevacizumab; Capecitabine; Carboplatin; Cetuximab; Docetaxel; Erlotinib; Etoposide; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Pemetrexed; Sorafenib; Temozolomide; Trastuzumab
  • Indications Breast cancer; Colon cancer; Lung cancer; Pancreatic cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 09 Dec 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 04 Jun 2013 Trial was terminated early due to discontinued development of R1507, according to ASCO 2013 abstract.
    • 04 Jun 2013 Results were presented at 49th Annual Meeting of the American Society of Clinical Oncology (ASCO 2013).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top